Thermo Fisher Scientific (TMO)

Hold Current rating · 3 reports

Coverage summary

Aardvark Labs Capital Research has covered Thermo Fisher Scientific (TMO) since April 24, 2026. The company is in the Healthcare sector. This page lists 3 reports: 3 earnings recaps.

The latest is the Q3 2026 Earnings Recap, published October 25, 2026. That report moved the rating from Outperform to Hold. The rating has changed once since coverage began.

Translations: 2 in Chinese.

Rating history

April 24, 2026 First rating: Outperform Q1 2026 Earnings Recap
October 25, 2026 Outperform → Hold Q3 2026 Earnings Recap

All TMO reports

2026-10-25

Hold Recap: Q3 2026

Six Percent Organic and Another Raise, but After an 18% Run the Price Already Reflects the Recovery: Downgrading Thermo Fisher to Hold

2026-07-24

Outperform Recap: Q2 2026

Thermo Fisher: Organic Growth Reaccelerates to 5%, the Guide Gets a Real Organic Raise, and the Ramp Thesis Is Vindicated

2026-04-24

Outperform Recap: Q1 2026

Thermo Fisher: Beat-and-Raise Masks a 1% Organic Print, and the 9% Sell-Off Overshoots a Calendar-Driven Quarter